Head-To-Head Review: Redhill Biopharma (NASDAQ:RDHL) & BeOne Medicines (NASDAQ:ONC)

Redhill Biopharma (NASDAQ:RDHL) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Profitability

This table compares Redhill Biopharma and BeOne Medicines’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
BeOne Medicines	1.38%	5.52%	3.17%

Risk & Volatility

Redhill Biopharma has a beta of 4.83, meaning that its stock price is 383% more volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500.

Earnings & Valuation

This table compares Redhill Biopharma and BeOne Medicines”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$8.04 million	0.68	-$8.27 million	$486.75	0.00
BeOne Medicines	$3.81 billion	9.93	-$644.79 million	$0.51	625.61

Redhill Biopharma has higher earnings, but lower revenue than BeOne Medicines. Redhill Biopharma is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 6.6% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Redhill Biopharma and BeOne Medicines, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1	0	0	0	1.00
BeOne Medicines	1	1	12	0	2.79

BeOne Medicines has a consensus price target of $365.79, suggesting a potential upside of 14.64%. Given BeOne Medicines’ stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than Redhill Biopharma.

Summary

BeOne Medicines beats Redhill Biopharma on 10 of the 14 factors compared between the two stocks.

About Redhill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.